山东医学高等专科学校学报
山東醫學高等專科學校學報
산동의학고등전과학교학보
JOURNAL OF SHANDONG MEDICAL COLLEGE
2009年
4期
290-292
,共3页
甲泼尼龙%紫癜,过敏性%肾炎%血浆置换
甲潑尼龍%紫癜,過敏性%腎炎%血漿置換
갑발니룡%자전,과민성%신염%혈장치환
Methylprednisolone%Purpura%Henoch-Schonlein%Nephritis%Plasmapheresis
目的 观察早期血浆置换(PP)联合甲基强的松龙(MP)冲击治疗过敏性紫癜肾炎(HSPN)的临床疗效.方法 分析10例行早期PP联合MP冲击治疗的HSPN患者的临床资料,并与12例甲基强的松龙冲击治疗的HSPN患者、18例应用常规剂量肾上腺皮质激素治疗的HSPN患者作对比.结果 经早期PP联合MP冲击治疗后,8例患者尿常规阴转或明显好转,总有效率达80%.在使尿微量蛋白减低方面,较单用MP冲击治疗患者、常规治疗患者均显示了明显的优越性(P<0.05或P<0.01).在PP联合MP冲击治疗过程中,无严重并发症发生.结论 早期血浆置换联合甲基强的松龙冲击治疗是治疗HSPN可取的有效的方法.
目的 觀察早期血漿置換(PP)聯閤甲基彊的鬆龍(MP)遲擊治療過敏性紫癜腎炎(HSPN)的臨床療效.方法 分析10例行早期PP聯閤MP遲擊治療的HSPN患者的臨床資料,併與12例甲基彊的鬆龍遲擊治療的HSPN患者、18例應用常規劑量腎上腺皮質激素治療的HSPN患者作對比.結果 經早期PP聯閤MP遲擊治療後,8例患者尿常規陰轉或明顯好轉,總有效率達80%.在使尿微量蛋白減低方麵,較單用MP遲擊治療患者、常規治療患者均顯示瞭明顯的優越性(P<0.05或P<0.01).在PP聯閤MP遲擊治療過程中,無嚴重併髮癥髮生.結論 早期血漿置換聯閤甲基彊的鬆龍遲擊治療是治療HSPN可取的有效的方法.
목적 관찰조기혈장치환(PP)연합갑기강적송룡(MP)충격치료과민성자전신염(HSPN)적림상료효.방법 분석10례행조기PP연합MP충격치료적HSPN환자적림상자료,병여12례갑기강적송룡충격치료적HSPN환자、18례응용상규제량신상선피질격소치료적HSPN환자작대비.결과 경조기PP연합MP충격치료후,8례환자뇨상규음전혹명현호전,총유효솔체80%.재사뇨미량단백감저방면,교단용MP충격치료환자、상규치료환자균현시료명현적우월성(P<0.05혹P<0.01).재PP연합MP충격치료과정중,무엄중병발증발생.결론 조기혈장치환연합갑기강적송룡충격치료시치료HSPN가취적유효적방법.
Objective To observe the curative effect of the combined use of plasmapheresis(PP) and methyl-prednisolone(MP) on Henoch-Schonlein purpura nephritis(HSPN).Methods A retrospective research was performed to analyze the clinical effect on 10 adolescents with HSPN treated by PP and MP pulse therapy(the PP+MP group),12 cases by MP pulse therapy(MP group),15 cases by common dose of adrenocortical hprmones(the control group).Urine routine factors and urine trace protein were analyzed before and after these therapies.Results In PP+MP group,8 patients showed recovery or obvious improvement in urine routine factors,and the total effective rate was 80%,much higher than in other groups.The concentration of urine trace protein was obviously lower in PP+MP group than in those in MP group and the control group after being treated(PP<0.05).No serious complications were found.ConclusionEarly plasmapheresis and pulse therapy with methyl-prednisolone should be an effective therapy for Henoch-Schnlein purpura nephritis.